KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Debt to Equity (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Debt to Equity data on record, last reported at $0.68 in Q4 2025.

  • For Q4 2025, Debt to Equity rose 3.32% year-over-year to $0.68; the TTM value through Dec 2025 reached $0.68, up 3.32%, while the annual FY2025 figure was $0.68, 3.32% up from the prior year.
  • Debt to Equity reached $0.68 in Q4 2025 per CRL's latest filing, up from $0.64 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.19 in Q3 2021 and bottomed at $0.61 in Q3 2024.
  • Average Debt to Equity over 5 years is $0.86, with a median of $0.8 recorded in 2025.
  • Peak YoY movement for Debt to Equity: rose 12.36% in 2021, then plummeted 31.98% in 2023.
  • A 5-year view of Debt to Equity shows it stood at $1.05 in 2021, then decreased by 13.51% to $0.91 in 2022, then decreased by 19.09% to $0.73 in 2023, then decreased by 11.09% to $0.65 in 2024, then grew by 3.32% to $0.68 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.68 in Q4 2025, $0.64 in Q3 2025, and $0.69 in Q2 2025.